{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:48:50Z","timestamp":1790416130544,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ymthe.2025.11.017","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:19:19Z","timestamp":1763183959000},"page":"1172-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Artificial miRNA-mediated reduction of SNCA for the treatment of \u03b1-synucleinopathies"],"prefix":"10.1016","volume":"34","author":[{"given":"Bradford","family":"Elmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Wischhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanga Aishwarya","family":"Mahendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Ardinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Bladon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Rapaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameer","family":"Khader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-8749","authenticated-orcid":false,"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.11.017_bib1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.11.017_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.11.017_bib3","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.11.017_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.11.017_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41531-021-00196-5","article-title":"A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease","volume":"7","author":"Pedersen","year":"2021","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.11.017_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature17939","article-title":"Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression","volume":"533","author":"Soldner","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.017_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archneurol.2010.279","article-title":"SNCA variant associated with Parkinson disease and plasma alpha-synuclein level","volume":"67","author":"Mata","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1096\/fj.07-9348com","article-title":"Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain","volume":"22","author":"Fuchs","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2025.11.017_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neulet.2009.06.034","article-title":"A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease","volume":"461","author":"Sotiriou","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2025.11.017_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/epigenomes7010005","article-title":"SNCA Gene Methylation in Parkinson's Disease and Multiple System Atrophy","volume":"7","author":"Fedotova","year":"2023","journal-title":"Epigenomes"},{"key":"10.1016\/j.ymthe.2025.11.017_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/mds.26073","article-title":"Parkinson's disease correlates with promoter methylation in the alpha-synuclein gene","volume":"30","author":"Pihlstrom","year":"2015","journal-title":"Mov Disord."},{"key":"10.1016\/j.ymthe.2025.11.017_bib13","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.11.017_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","article-title":"alpha-Synuclein in synaptic function and dysfunction","volume":"46","author":"Sharma","year":"2023","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2025.11.017_bib15","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1093\/brain\/awad150","article-title":"Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease","volume":"146","author":"Calabresi","year":"2023","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.11.017_bib16","doi-asserted-by":"crossref","first-page":"14966","DOI":"10.1073\/pnas.0406283101","article-title":"Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions","volume":"101","author":"Chandra","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.017_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135633","article-title":"alpha-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.11.017_bib18","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1523\/JNEUROSCI.0618-11.2011","article-title":"alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies","volume":"31","author":"Lim","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.11.017_bib19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nbd.2019.01.004","article-title":"Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration","volume":"125","author":"Zharikov","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.11.017_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45078-3","article-title":"Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson's disease","volume":"13","author":"Sastre","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.11.017_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab247","article-title":"Viral alpha-synuclein knockdown prevents spreading synucleinopathy","volume":"3","author":"Menon","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymthe.2025.11.017_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","article-title":"Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration","volume":"25","author":"Drolet","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2025.11.017_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.expneurol.2007.10.012","article-title":"Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice","volume":"210","author":"Alvarez-Fischer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nbd.2005.08.018","article-title":"Mice lacking alpha-synuclein are resistant to mitochondrial toxins","volume":"21","author":"Klivenyi","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.11.017_bib25","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.017_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-Associated Virus-Based Gene Therapy for CNS Diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4103\/1673-5374.167783","article-title":"Gene therapy for Parkinson's disease: a decade of progress supported by posthumous contributions from volunteer subjects","volume":"10","author":"Bartus","year":"2015","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ymthe.2025.11.017_bib28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mt.2013.285","article-title":"Recombinant AAV as a platform for translating the therapeutic potential of RNA interference","volume":"22","author":"Borel","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib29","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.11.017_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.11.017_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/B978-0-12-386509-0.00014-4","article-title":"Generation of hairpin-based RNAi vectors for biological and therapeutic application","volume":"507","author":"Boudreau","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.11.017_bib33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.11.017_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrm2632","article-title":"Biogenesis of small RNAs in animals","volume":"10","author":"Kim","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.omtn.2018.12.004","article-title":"Optimizing Synthetic miRNA Minigene Architecture for Efficient miRNA Hairpin Concatenation and Multi-target Gene Knockdown","volume":"14","author":"Rousset","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.11.017_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2144\/000112203","article-title":"Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown","volume":"41","author":"Sun","year":"2006","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2025.11.017_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkl143","article-title":"Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC\/miR-155","volume":"34","author":"Chung","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.11.017_bib38","first-page":"1316","article-title":"A strategy for the generation, characterization and distribution of animal models","volume":"6","author":"Baptista","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2025.11.017_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185001","article-title":"Cross-species efficacy of AAV-mediated ARSA replacement for Metachromatic Leukodystrophy","volume":"135","author":"Ramachandran","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.11.017_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nprot.2014.043","article-title":"Mapping the miRNA interactome by cross-linking ligation and sequencing of hybrids (CLASH)","volume":"9","author":"Helwak","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2025.11.017_bib41","series-title":"Scalable and Deep Profiling of mRNA Targets for Individual microRNAs with Chimeric eCLIP","author":"Manakov","year":"2022"},{"key":"10.1016\/j.ymthe.2025.11.017_bib42","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.molcel.2014.03.049","article-title":"Unambiguous identification of miRNA:target site interactions by different types of ligation reactions","volume":"54","author":"Grosswendt","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2025.11.017_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.08.052","article-title":"AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer's disease","author":"Hogestyn","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib44","first-page":"1","article-title":"Protein aggregation and degradation mechanisms in neurodegenerative diseases","volume":"2","author":"Takalo","year":"2013","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/j.ymthe.2025.11.017_bib45","doi-asserted-by":"crossref","first-page":"19573","DOI":"10.1073\/pnas.1005005107","article-title":"alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction","volume":"107","author":"Greten-Harrison","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.017_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.crneur.2022.100049","article-title":"Understanding them to understand ourselves: The importance of NHP research for translational neuroscience","volume":"3","author":"Lear","year":"2022","journal-title":"Curr. Res. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib47","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0192623318803867","article-title":"Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products","volume":"46","author":"Assaf","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymthe.2025.11.017_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2025.11.017_bib50","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.11.017_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.111024","article-title":"Advances in animal models of Parkinson's disease","volume":"215","author":"He","year":"2024","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ymthe.2025.11.017_bib53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal models of alpha-synucleinopathy for Parkinson disease drug development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2025.11.017_bib54","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3233\/JPD-212847","article-title":"A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model","volume":"11","author":"Polinski","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.11.017_bib55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/brain\/awl382","article-title":"Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain","volume":"130","author":"Eslamboli","year":"2007","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.11.017_bib56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gks797","article-title":"siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse","volume":"41","author":"Boudreau","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.11.017_bib58","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1038\/s41467-025-60374-4","article-title":"Translation suppresses exogenous target RNA-mediated microRNA decay","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.11.017_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cell.2010.03.009","article-title":"Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP","volume":"141","author":"Hafner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.11.017_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2025.11.017_bib61","article-title":"Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue","author":"Dhavale","year":"2023","journal-title":"bioRxiv."},{"key":"10.1016\/j.ymthe.2025.11.017_bib62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","article-title":"Structures of alpha-synuclein filaments from human brains with Lewy pathology","volume":"610","author":"Yang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.017_bib63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","article-title":"Structures of alpha-synuclein filaments from multiple system atrophy","volume":"585","author":"Schweighauser","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.017_bib64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2017.07.018","article-title":"Distinct alpha-Synuclein strains and implications for heterogeneity among alpha-Synucleinopathies","volume":"109","author":"Peng","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.11.017_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-Nejad","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.11.017_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.11.017_bib68","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.11.017_bib69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.11.017_bib70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.11.017_bib71","article-title":"Scalable and deep profiling of mRNA targets for individual microRNAs with chimeric eCLIP","author":"Manakov","year":"2022","journal-title":"bioRxiv"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625009578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625009578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:37:56Z","timestamp":1770223076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625009578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1525001625009578"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.11.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial miRNA-mediated reduction of SNCA for the treatment of \u03b1-synucleinopathies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}